Threshold Pharmaceuticals (THLD) +6.3% premarket after earning a $30M milestone payment from...
Friday, January 25, 9:26 AM ETThreshold Pharmaceuticals (THLD) +6.3% premarket after earning a $30M milestone payment from drug partner Merck (MRK), which started a late-stage study of THLD's pancreatic cancer drug. TH-302 is an investigational hypoxia-targeted drug designed to be activated under severe tumor hypoxic conditions, a hallmark of many cancers.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles